Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Botulinum toxin A - Ipsen

Drug Profile

Botulinum toxin A - Ipsen

Alternative Names: AboBoNT-A; AbobotulinumtoxinA; ALLUZIENCE; Azzalure; BoNT-A; BTX-A-HAC; BTX-A-HAC NG; Clostridium botulinum toxin type A haemagglutinin complex; Dysport; DYSPORT AESTHETIC; Dysport NG; Dysport RU; Dysport Solution; Dysport® Next Generation; Reloxin

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Health Protection Agency Porton Down; Ipsen Limited
  • Developer Biosintetica; Galderma; Ipsen Limited; Medicis Pharmaceutical Corporation; Valeant Pharmaceuticals International
  • Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antipruritics; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Recombinant proteins; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Torticollis; Cerebral palsy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Blepharospasm; Equinus foot deformity; Facial wrinkles; Fissure in ano; Glabellar lines; Hyperhidrosis; Muscle spasticity; Neurogenic bladder; Spasm; Torticollis
  • Phase III Migraine; Musculoskeletal disorders; Urinary incontinence
  • Phase II/III Pain
  • Phase II Gilles de la Tourette's syndrome; Gingival disorders; Vulvodynia
  • Discontinued Hallux valgus

Most Recent Events

  • 12 Oct 2023 Ipsen initiates enrolment in a phase III C-BEOND trial for Migraine in USA (NCT06047444)
  • 29 Sep 2023 Phase-III clinical trials in Migraine (Prevention) in USA (IM) (NCT06047457)
  • 21 Sep 2023 Ipsen plans a phase III trial for the prevention of Migraine in undisclosed location (NCT06047444)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top